Pre-grant Opposition To Daclatasvir Polymorph Patent In India
This article was originally published in PharmAsia News
Executive Summary
BMS faced two pre-grant oppositions in May to its Indian patent application for hepatitis C treatment daclatasvir, with one of the motions highlighting the lack of an inventive step as described under Section 3(d) of the Indian Patent Act.